Skip to main content
Clinical Trials/NCT02198976
NCT02198976RecruitingNot Applicable

Australian Barrett's Cohort With Dysplasia and Early Cancer Study

Professor Michael Bourke1 site in 1 country300 target enrollmentStarted: April 2014Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
300
Locations
1
Primary Endpoint
Number of Serious and Non-Serious Adverse Events

Study Overview

Brief Summary

The purpose of this study is to collect prospective observational data regarding endoscopic management and outcomes of patients with Barrett's oesophagus (BO) with high grade dysplasia and/or intramucosal carcinoma. To observe the natural history of patients with low grade dysplastic and non dysplastic Barrett's oesophagus

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to 99 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Can give informed consent to trial participation
  • Age greater than 18
  • Barrett's oesophagus

Exclusion Criteria

  • Age less than 18
  • Pregnant patients

Outcomes

Primary Outcomes

Number of Serious and Non-Serious Adverse Events

Time Frame: During the Barretts Excision

Collect prospective observational data on patients undergoing endoluminal therapy for dysplastic BO to determine * Long term risk of oesophageal adenocarcinoma (OAC) development * Long term efficacy (dysplasia and metaplasia free) in both long and short segment BO * Short and long term safety and complications * Comparison of the safety, long term efficacy, cost and patient tolerability between endoscopic mucosal resection (EMR) and radiofrequency ablation (RFA) Document the endoscopic location and characterise morphology of HGD/IMC in short and long segment BO Define the short term and long term causes of morbidity / mortality of patients undergoing ER This will be recorded on a datasheet, de-identified during the procedure.

Secondary Outcomes

  • Number of Participants with Serious and Non-Serious Adverse Events(Up to 5 years after procedure)

Investigators

Sponsor
Professor Michael Bourke
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Professor Michael Bourke

Director of Gastrointestinal Endoscopy

Western Sydney Local Health District

Study Sites (1)

Loading locations...

Similar Trials